BlossomHill Therapeutics, Inc. Share Price

Stocks

Real-time Estimate Cboe BZX 14:30:10 18/09/2026 BST			5-day change	1st Jan Change
27.18 ^USD	+1.34%		+24.69%	-

12:43pm	BlossomHill Therapeutics Q2 Loss Widens	MT
12:14pm	Earnings Flash (BLSM) BlossomHill Therapeutics Posts Q2 Loss $8.75 a Share	MT

NasdaqUSD

Markets		Quality
Nasdaq	BLSM	Delayed
CBOE	BLSM	Real-time

12:43pm	BlossomHill Therapeutics Q2 Loss Widens	MT
12:14pm	Earnings Flash (BLSM) BlossomHill Therapeutics Posts Q2 Loss $8.75 a Share	MT
09-15	BlossomHill Therapeutics Presents Updated Data from Ongoing Phase 1/2 Solara Trial Demonstrating Anti-Tumor Activity of Omni-EGFR Inhibitor BH-30643 in EGFR C797s-Positive NSCLC	CI
09-15	BlossomHill Drug Shows 45% Response Rate in Lung Cancer Trial	MT
09-01	Leerink Partners Initiates BlossomHill Therapeutics at Outperform, $36 Price Target	MT
09-01	JPMorgan Initiates BlossomHill Therapeutics at Overweight	MT
09-01	Guggenheim Initiates BlossomHill Therapeutics at Buy With $30 Price Target	MT
09-01	HC Wainwright Initiates BlossomHill Therapeutics at Buy With $35 Price Target	MT
08-18	BlossomHill Says BH-30643 Gets FDA Fast Track Designation in Non-Small Cell Lung Cancer	MT
08-18	Blossomhill Therapeutics Receives Fda Fast Track Designation for Bh-30643 for Treatment of Advanced Egfr C797s-Positive Nsclc	CI
08-11	BlossomHill Therapeutics Insider Bought Shares Worth $5,000,000, According to a Recent SEC Filing	MT
08-09	BlossomHill Therapeutics, Inc.(NasdaqGS:BLSM) added to NASDAQ Composite Index	CI
08-07	BlossomHill Therapeutics Shares Fall in Nasdaq Debut	MT

09-01	Leerink Partners Initiates BlossomHill Therapeutics at Outperform, $36 Price Target	MT
09-01	JPMorgan Initiates BlossomHill Therapeutics at Overweight	MT
09-01	Guggenheim Initiates BlossomHill Therapeutics at Buy With $30 Price Target	MT
09-01	HC Wainwright Initiates BlossomHill Therapeutics at Buy With $35 Price Target	MT

12:00pm	BlossomHill Therapeutics Reports Second Quarter 2026 Financial Results	GL
09-15	BlossomHill Therapeutics Presents Updated Data from Ongoing Phase 1/2 SOLARA Trial Demonstrating Encouraging Anti-Tumor Activity of OMNI-EGFR™ Inhibitor BH-30643 in EGFR C797S-Positive NSCLC at IASLC 2026 World Conference on Lung Cancer	GL
09-03	BlossomHill Therapeutics to Present at the 8th Annual RAS-Targeted Drug Development Summit & H.C. Wainwright 28th Annual Global Investment Conference	GL
09-01	BlossomHill Therapeutics to Present Updated Data from Ongoing Phase 1/2 SOLARA Trial of its Macrocyclic OMNI-EGFR™ Inhibitor, BH-30643, in EGFR-mutant NSCLC at the 2026 World Conference on Lung Cancer	GL
09-01	BlossomHill Therapeutics to Present Updated Data from Ongoing Phase 1/2 SOLARA Trial of its Macrocyclic OMNI-EGFR™ Inhibitor, BH-30643, in EGFR-mutant NSCLC at the 2026 World Conference on Lung Cancer	AQ

Manager	Title	Age	Since
Jing Rong Jean Cui CEO	Chief Executive Officer	62	31/05/2020
Jason Keyes DFI	Director of Finance/CFO	55	30/04/2025
Zachary Zimmerman CTO	Chief Tech/Sci/R&D Officer	-	-

Director	Title	Age	Since
Jing Rong Jean Cui BRD	Director/Board Member	62	31/05/2020
Bihua Chen BRD	Director/Board Member	57	31/01/2021
Yi Shan Li CHM	Chairman	61	31/05/2020

Date	Insider	Type	Main position	Quantity	% Market Cap.
10/08/26	Sundeep Agrawal	Conversion	Director	1,157,048	3.6917%
10/08/26	Cormorant Asset Management LP	Conversion	Company	6,915,568	22.0651%
10/08/26	Vincent Liptak	Buy	General Counsel	47,574	0.1518%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
BLOSSOMHILL THERAPEUTICS, INC.	+1.34%	+24.69%	-	-	822M
LONZA GROUP AG	+0.59%	+3.46%	+1.07%	+29.53%	46.18B
IQVIA HOLDINGS INC.	-0.60%	+4.72%	+44.32%	+27.27%	44.35B
REVOLUTION MEDICINES, INC.	-0.24%	-3.15%	+349.53%	+520.09%	42.21B
BEONE MEDICINES AG	-0.13%	+3.41%	+6.40%	+76.45%	40.19B
CELLTRION, INC.	+1.75%	-0.28%	+12.42%	+41.11%	29.83B
MEDPACE HOLDINGS, INC.	+0.63%	+5.49%	+23.57%	+119.72%	17.17B
ASCENDIS PHARMA A/S	-0.61%	-8.49%	-	-	15.7B
EUROFINS SCIENTIFIC SE	+0.68%	+9.50%	+23.71%	+40.71%	15.32B
ICON PUBLIC LIMITED COMPANY	-1.91%	+2.41%	-3.16%	-35.16%	13.09B
Average	+0.17%	+4.05%	+57.23%	+102.46%	26.49B
Weighted average by Cap.	+0.14%	+1.80%	+72.98%	+125.01%